Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (409)	4/23/1999 10:09:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 550

>> No interest, or everybody is hiding??? << Nobody is interested in innovative approaches to cancer. They're daytrading IBM. The world is insane.

To: Miljenko Zuanic who wrote (409)	4/25/1999 12:18:00 AM
From: smh	Read Replies (2) \| Respond to of 550

EU show growing interest for start-up or development stage bts, so EU public offering or/and VC investment is one option, beside finance support from regional marketing partner MZ, Your statement makes more sense to me than what the co. said in either the cc or the release. The benefits of SUGN EU, as presented, were a little nebulous. Organizationally, it makes sense to delegate EU marketing and clinical, while the home boys stay focused. In any case, if this scheme allows SUGN to keep a bigger piece of the pie ultimately, great. The cc rekindled what I find to be the intriguing subject of off label potential. It seems to me this off label potential may represent real (but unrecognized even though obviously part of their strategy)"leverage" for sugn and others. Thoughts? SMH